PL
Pulse Biosciences, Inc.
PLSE · NASDAQ
$50.61 +2.55% (+$1.26)
1M +7.64%
Market Cap $3.50B
P/E Ratio -
Div. Yield -
ROE 94.42%
Bulios Fair Price
$35.44
30.0% downside
Current Price
$50.61
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PLSE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 2,955.87x
P/B 35.20x
P/E N/A
Growth
0 /100
Declining Rev. growth 20.63%
EPS growth N/A
Book val. growth N/A
Profitability
0 /100
Weak Gross margin 21.60%
FCF margin 5,180.42%
Net margin 6,755.78%
Quality
0 /100
Poor ROIC 78.14%
Asset turnover 0.01x
ROE 94.42%
Debt
100 /100
Low Debt/Equity 0.07x
Current ratio 9.63x
Int. coverage N/A
Stability
34 /100
Moderate Beta 1.63x
Profitable years 0
EPS volatility 35.12%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PLSE
Online
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Paul Arthur LaViolette
Employees
116
Headquarters
Miami
Upcoming events
04 NOV
Earnings
Upcoming earnings report